Dyadic International, Inc. (DYAI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol DYAI
- Company Dyadic International, Inc.
- Price $1.49
- Changes Percentage 22.13
- Change 0.27
- Day Low $1.22
- Day High $1.79
- Year High $2.67
- Year Low $0.93
- Market Cap $44,088,206
- Price Avg 50 EMA (D) $1.12
- Price Avg 200 EMA (D) $1.45
- Exchange NASDAQ
- Volume 466,663
- Average Volume 24,621
- Open $1.24
- Previous Close $1.22
- EPS -0.23
- PE -6.48
- Earnings Announcement 2025-03-26 10:00:00
- Shares Outstanding $29,589,400
Company brief: DYADIC INTERNATIONAL, INC. (DYAI )
- Healthcare
- Biotechnology
- Mr. Mark A. Emalfarb
- https://www.dyadic.com
- US
- N/A
- 01-16-2008
- US26745T1016
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Corporation News
Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript
seekingalpha.com -- Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Ping Rawson - CFO Mark Emalfarb - President & CEO Joseph Hazelton - COO Pat...